Antidepressant Use Late in Pregnancy Linked to Bleeding Risk: Study

The use of certain antidepressants during the late stages of pregnancy may increase the risk of women suffering bleeding problems, with side effects of Effexor potentially carrying the largest risk, according to the findings of new research.  

In a study published last week in the British Medical Journal, Harvard researchers suggested that pregnant women who are taking antidepressants at the time they give birth run a larger risk of suffering postpartum hemorrhaging than those who do not take the drugs.

The findings are the latest in a number of studies that indicate pregnancy use of antidepressants, including those known as selective serotonin reuptake inhibitors (SSRIs), which include popular drugs like Paxil, Prozac and Zoloft, carry dangerous side effects for women and their children.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

The study looked at data on 106,000 pregnant women between the ages of 12 and 55 who were diagnosed with mood or anxiety disorder. They divided the women based on how recently before delivery they were exposed to antidepressants.

Researchers found that women who took no antidepressants had a 2.8% risk of bleeding problems after delivery. However, those who took non-SSRIs at the time of delivery had a 3.8% risk and those who took SSRIs at the time of delivery had a 4.0% risk of bleeding problems. The use of Effexor carried the highest risk, with a 1.9-fold increased risk; nearly double the risk of postpartum hemorrhaging experienced by women who took no antidepressants.

“Compared with no exposure, women with current exposure to serotonin reuptake inhibitors had a 1.47-fold increased risk of postpartum hemorrhage and women with current non-serotonin reuptake inhibitor exposure had a 1.39-fold increased risk,” the researchers determined. “All types of selective serotonin reuptake inhibitors available for analysis and [Effexor], a serotonin norepinephrine reuptake inhibitor, were significantly associated with postpartum hemorrhage.”

Other Antidepressant Risks From Pregnancy Use

The study is just the latest to highlight concerns about the safety of using certain antidepressants during pregnancy. In addition to potential health concerns for the mother highlighted by this most recent research, a number of prior studies have linked use of certain antidepressants to birth defect risks, especially when the medication is used during the first trimester, which is a time when many women do not yet know they are pregnant.

The risk of antidepressant birth defects associated with the use of SSRIs has been a known issue for years. In 2006, the FDA released a public health advisory that warned side effects of antidepressants could cause serious injury for children, including a six-fold increase in the risk of the child suffering from Persistent Pulmonary Hypertension in Newborns (PPHN).

A number of families have filed Paxil birth defect lawsuits and Zoloft lawsuits in recent years, alleging that the manufacturers of these popular SSRI antidepressants withheld information about the risk of using the medications while pregnant.

More recently, momentum has been building for Effexor birth defect lawsuits involving the widely used SNRI antidepressant.

Earlier this month, the U.S. Judicial Panel on Multidistrict Litigation (JPML) established coordinated pretrial proceedings for all Effexor cases filed in the federal court system, assigning the litigation to U.S. District Judge Cynthia M. Rufe in the Eastern District of Pennsylvania, who is already presiding over the federal Zoloft litigation..


Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal
BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal (Posted yesterday)

A BioZorb lawsuit has been filed by several breast cancer survivors after the BioZorb implants moved out of place and failed to dissolve int he body, requiring surgical removal.

Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October
Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October (Posted yesterday)

A U.S. District Court judge has scheduled a fairness hearing for October in order to determine whether final approval should be granted to a $25 million Philips CPAP recall settlement agreement, which would pay former users $25 million to pay for future medical monitoring needs.